PA
VERV

Profund Advisors’s Verve Therapeutics VERV Stock Holding History

Profund Advisors’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,210
Closed -$182K – 1094
2025
Q2 		$182K Sell
16,210
-7,396
-31% -$42.2K 0.01% 925
2025
Q1 		$108K Sell
23,606
-3,028
-11% -$20.3K ﹤0.01% 947
2024
Q4 		$150K Sell
26,634
-14,757
-36% -$83.2K 0.01% 1042
2024
Q3 		$200K Buy
41,391
+13,477
+48% +$78.3K 0.01% 1053
2024
Q2 		$136K Sell
27,914
-38,883
-58% -$244K 0.01% 1026
2024
Q1 		$887K Buy
66,797
+17,406
+35% +$231K 0.03% 390
2023
Q4 		$689K Buy
49,391
+2,298
+5% +$28.5K 0.03% 421
2023
Q3 		$624K Buy
47,093
+3,491
+8% +$56.2K 0.03% 406
2023
Q2 		$818K Sell
43,602
-5,125
-11% -$85.4K 0.04% 370
2023
Q1 		$703K Buy
+48,727
New +$954K 0.04% 400

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Profund Advisors's VERV Position: Q3 2025 in Review

Profund Advisors sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 16,210 shares — an estimated $182K sold.

Profund Advisors first reported a position in VERV in Q1 2023 and held it in 10 quarters. The position peaked at $887K in Q1 2024. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Profund Advisors reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Profund Advisors sold 16,210 Verve Therapeutics shares in Q3 2025, an estimated $182K.
  • Profund Advisors first reported a position in Verve Therapeutics in Q1 2023 and held it in 10 quarters.
  • Profund Advisors's Verve Therapeutics position peaked at $887K in Q1 2024.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Profund Advisors's 13F filing for Q3 2025, filed 6 Nov 2025.